Pianopooh

10+ Year Member
Jan 23, 2006
132
1
Status
Pharmacist
F.D.A. Approves Eli Lilly Blood Thinner, With a Warning

Article Tools Sponsored By
By THE ASSOCIATED PRESS
Published: July 10, 2009

WASHINGTON (AP) — The Food and Drug Administration approved a highly anticipated blood thinner from Eli Lilly on Friday, though the drug must carry the agency’s sternest warning because of its risk of causing bleeding.

The approval makes Lilly’s Effient the first real competition to the blood thinner Plavix, which is made by Sanofi-Aventis and Bristol-Myers Squibb and is the world’s second-best selling medication behind the cholesterol pill Lipitor.

The F.D.A. delayed its decision on Effient several times during an 18-month review as agency officials weighed the drug’s benefits and risks.

A Lilly study of more than 13,000 patients found that Effient prevented more heart attacks than Plavix, but caused more internal bleeding.

The F.D.A. said Effient would carry a boxed warning to alert physicians to the risks of “significant, sometimes fatal, bleeding.” The boxed warning is reserved for issues that can cause serious injury or death.

Effient should not be taken by patients with a history of bleeding, stroke or who are undergoing an operation, the F.D.A. said.

“Physicians must carefully weigh the potential benefits and risks of Effient as they decide which patients should receive the drug,” said Dr. John Jenkins, director of new drugs for the F.D.A.

The drug offers an alternative treatment for preventing dangerous blood clots that can lead to heart attack or stroke, Dr. Jenkins said.

The boxed warning could curb sales, but not to a large extent, said Les Funtleyder, an analyst at Miller Tabak & Company, an institutional trading firm.

“The F.D.A. has been a lot more liberal with black box warnings than it was in the past, and in a way the black box has lost some of the meaning it had when it was rare,” Mr. Funtleyder said. “But it still has the ability to somewhat limit sales.”

Company studies showed 7 percent of patients taking Effient had nonfatal heart attacks, compared with 9.1 percent of patients taking Plavix. Despite lower rates of certain heart attacks, the actual rates of death for the drugs were similar.

Lilly, based in Indianapolis, developed Effient, known chemically as prasugrel, with the Daiichi Sankyo Company of Japan. They will share revenue.

Wall Street analysts said Effient sales could reach $1 billion annually, compared with $4.9 billion in sales for Plavix last year.

Like Plavix, Effient prevents blood platelets from sticking together and forming potentially dangerous clots. But while Plavix is approved for use in a wide range of patients, Effient is approved only for those undergoing angioplasty, a procedure in which an inflatable balloon is used to clear arteries clogged with plaque, which are often propped open with a stent.

Approval of Effient was considered crucial for Lilly because patents protecting its four best-selling drugs expire by 2013.

Stock in Lilly rose 32 cents, to $33.32 a share.
Source: http://www.nytimes.com/2009/07/11/health/policy/11drug.html?_r=1&ref=health
 

Priapism321

Bursting with enthusiasm
10+ Year Member
5+ Year Member
Apr 17, 2007
1,424
3
Status
Pharmacist

WVUPharm2007

imagine sisyphus happy
15+ Year Member
Jun 23, 2003
13,743
3,702
36
Born: Parkersburg, WV | Now: Montgomery TWP, PA
Status
Pharmacist
This new drug is efficient, at inducing intracranial hemorrhages...
Hell yeah, new market for Nimotop, baby. I knew that Bayer stock would pay off eventually.
 

Priapism321

Bursting with enthusiasm
10+ Year Member
5+ Year Member
Apr 17, 2007
1,424
3
Status
Pharmacist
Hell yeah, new market for Nimotop, baby. I knew that Bayer stock would pay off eventually.
Lord knows you are not going to get there with sorafenib...although they also already have the "next generation" sorafenib in phase II trials. Bless it...
 

WVUPharm2007

imagine sisyphus happy
15+ Year Member
Jun 23, 2003
13,743
3,702
36
Born: Parkersburg, WV | Now: Montgomery TWP, PA
Status
Pharmacist
Lord knows you are not going to get there with sorafenib...although they also already have the "next generation" sorafenib in phase II trials. Bless it...
I have no idea what the hell that is. I'll take a stab at it...its some obscure oncology drug...
 

Praziquantel86

Moderator Emeritus
10+ Year Member
7+ Year Member
Oct 28, 2008
2,572
40
Status
Fellow [Any Field]
Hell yeah, new market for Nimotop, baby. I knew that Bayer stock would pay off eventually.
I love the warnings about inadvertent IV use on that stuff. It boggles the mind that you could draw liquid out of a capsule and inadvertently inject it. Insanity.

Avelox hasn't been helping your portfolio? I feel like it's skyrocketed since the levofloxacin dose recommendations went up.